In a filing, LifeMD Inc revealed its Chief Acquisition Officer Alvarez Nicholas P unloaded Company’s shares for reported $0.44 million on Sep 10 ’25. In the deal valued at $5.92 per share,75,000 shares were sold. As a result of this transaction, Alvarez Nicholas P now holds 605,000 shares worth roughly $4.01 million.
Then, Alvarez Nicholas P bought 75,000 shares, generating $459,000 in total proceeds.
Before that, Schreiber Justin sold 25,000 shares. LifeMD Inc shares valued at $249,690 were divested by the Chairman and CEO at a price of $9.99 per share. As a result of the transaction, Schreiber Justin now holds 2,475,721 shares, worth roughly $16.41 million.
BTIG Research reiterated its LifeMD Inc [LFMD] rating to a Buy in a research note published on June 18, 2025; the price target was $18. A number of analysts have revised their coverage, including Lake Street’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Mizuho began covering LFMD with “Neutral” recommendation on December 04, 2024.
Price Performance Review of LFMD
On Tuesday, LifeMD Inc [NASDAQ:LFMD] saw its stock fall -4.47% to $6.63. Over the last five days, the stock has lost -2.36%. LifeMD Inc shares have risen nearly 41.67% since the year began. Nevertheless, the stocks have risen 33.94% over the past one year. While a 52-week high of $15.84 was reached on 06/23/25, a 52-week low of $3.99 was recorded on 03/10/25.
Levels Of Support And Resistance For LFMD Stock
The 24-hour chart illustrates a support level at 6.39, which if violated will result in even more drops to 6.15. On the upside, there is a resistance level at 6.93. A further resistance level may holdings at 7.23.
How much short interest is there in LifeMD Inc?
A steep rise in short interest was recorded in LifeMD Inc stocks on 2025-09-15, dropping by -1.31 million shares to a total of 4.97 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 6.28 million shares. There was a decline of -26.36%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 05, 2024 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $12 price target.
